Examining the effect of Tranexamic Acid (TXA) on the functional fibrinolysis assay in patients with hereditary bleeding disorder (HBD) compared with healthy controls.
Not Applicable
- Conditions
- Hereditary Bleeding Disorder (Haemophilia A and B, Von Willebrand disease)Blood - Clotting disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
- Registration Number
- ACTRN12615000311550
- Lead Sponsor
- Alfred Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
One of Hereditary Bleeding Disorder = Haemophilia A, Haemophilia B, or rarer coagulation factor deficiencies {such as factor XI deficiency} and von Willebrand Disease)
Exclusion Criteria
Pregnant or breastfeeding
Past history of thrombosis
Past history of renal disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We aim to evaluate the impact of TXA on functional fibrionolysis by enrolling patients with hereditary bleeding disorders and healthy controls into the proposed study.<br><br>In this study we will examine the rate of clot lysis using the new clot lysis assay. The principle of this turbidometric assay is continuous monitoring of clot formation and lysis by light transmission at 405 nm in a 96 well plate. <br>[Baseline and at 4 hours after ingestion of 1 gram of Tranexamic acid for patient group and baseline, 2, 4 and 8 hours for control group.]
- Secondary Outcome Measures
Name Time Method A[NA]